Global Patent Index - EP 3778623 A1

EP 3778623 A1 20210217 - PHARMACEUTICAL COMPOSITIONS

Title (en)

PHARMACEUTICAL COMPOSITIONS

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Title (fr)

COMPOSITIONS PHARMACEUTIQUES

Publication

EP 3778623 A1 20210217 (EN)

Application

EP 20185463 A 20140314

Priority

  • US 201361792440 P 20130315
  • EP 14724574 A 20140314
  • US 2014029421 W 20140314

Abstract (en)

The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.

IPC 8 full level

C07K 7/54 (2006.01); A61K 38/12 (2006.01)

CPC (source: EP IL RU US)

A61K 9/08 (2013.01 - EP IL US); A61K 9/10 (2013.01 - EP IL US); A61K 9/146 (2013.01 - EP IL US); A61K 38/08 (2013.01 - EP IL RU US); A61K 38/12 (2013.01 - EP IL US); A61K 45/06 (2013.01 - EP IL US); A61K 47/10 (2013.01 - EP IL RU US); A61K 47/12 (2013.01 - IL RU US); A61K 47/24 (2013.01 - IL RU US); A61K 47/38 (2013.01 - IL US); A61K 47/541 (2017.08 - EP IL US); A61K 47/542 (2017.08 - EP IL US); A61K 47/544 (2017.08 - EP IL US); A61P 3/00 (2018.01 - EP IL); A61P 3/04 (2018.01 - EP IL); A61P 3/10 (2018.01 - EP IL); A61P 5/02 (2018.01 - EP IL); A61P 5/04 (2018.01 - EP IL); A61P 5/10 (2018.01 - EP IL); A61P 5/18 (2018.01 - EP IL); A61P 43/00 (2018.01 - EP IL); C07K 7/06 (2013.01 - IL RU); C07K 14/435 (2013.01 - IL RU)

Citation (applicant)

  • US 8349797 B2 20130108 - DONG ZHENG XIN [US], et al
  • HOLFORD, N. H. G.SCHEINER, L. B., CLIN. PHARMACOKINET., vol. 6, 1981, pages 429 - 453
  • LOEWE, S.MUISCHNEK, H., ARCH. EXP. PATHOL. PHARMACOL., vol. 114, 1926, pages 313 - 326
  • CHOU, T. C.TALALAY, P., ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55
  • NATURE CLINICAL PRACTICE ENDOCRINOLOGY AND METABOLISM, vol. 2, no. 6, 2006, pages 318
  • "GenBank", Database accession no. CH471077
  • FAROOQI ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 2, July 2000 (2000-07-01), pages 253 - 262
  • XIANG ET AL.: "Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist", BIOCHEMISTRY, vol. 49, no. 22, 8 June 2010 (2010-06-08), pages 45 83 - 600
  • ROUBERT ET AL., JOURNAL OF ENDOCRINOLOGY, vol. 207, 2010, pages 177 - 183
  • NENG J MED, vol. 356, no. 3, 2007, pages 237
  • NATURE GENETICS, 1998, pages 155
  • CELL METABOLISM, vol. 3, 2006, pages 135
  • ANNALS ACAD MED, vol. 38, no. 1, 2009, pages 34
  • KAISER, E.COLESCOT, R. L.BOSSINGE, C. D.COOK, P. I., ANAL. BIOCHEM., vol. 34, 1990, pages 595 - 598
  • VOJKOVSKY, T., PEPT. RES., vol. 8, 1995, pages 236 - 237

Citation (search report)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014144842 A2 20140918; WO 2014144842 A3 20150409; AU 2014228460 A1 20151001; AU 2014228460 B2 20181101; AU 2019200101 A1 20190131; AU 2019200101 B2 20210204; AU 2021202699 A1 20210527; AU 2023204625 A1 20230803; BR 112015023409 A2 20170718; BR 112015023409 A8 20191203; BR 112015023409 B1 20231128; CA 2906782 A1 20140918; CA 2906782 C 20231003; CA 3209602 A1 20140918; CN 105518021 A 20160420; CN 115957296 A 20230414; CN 115957297 A 20230414; DK 2970389 T3 20201026; EP 2970389 A2 20160120; EP 2970389 B1 20200819; EP 3778623 A1 20210217; ES 2825076 T3 20210514; FR 21C1059 I1 20220121; FR 21C1059 I2 20221202; HK 1220702 A1 20170512; IL 241378 A0 20151130; IL 241378 B 20220101; IL 288961 A 20220201; JP 2016516062 A 20160602; JP 2019189619 A 20191031; JP 2022065117 A 20220426; JP 6538025 B2 20190703; KR 102378943 B1 20220325; KR 20160020405 A 20160223; NL 301149 I1 20211208; NL 301149 I2 20221124; NO 2021051 I1 20240805; PL 2970389 T3 20210308; PT 2970389 T 20201021; RU 2015143965 A 20170424; RU 2019116003 A 20190717; RU 2690377 C2 20190603; US 11129869 B2 20210928; US 2016022764 A1 20160128; US 2022160818 A1 20220526

DOCDB simple family (application)

US 2014029421 W 20140314; AU 2014228460 A 20140314; AU 2019200101 A 20190108; AU 2021202699 A 20210430; AU 2023204625 A 20230712; BR 112015023409 A 20140314; CA 2906782 A 20140314; CA 3209602 A 20140314; CN 201480026783 A 20140314; CN 202211043853 A 20140314; CN 202211043877 A 20140314; DK 14724574 T 20140314; EP 14724574 A 20140314; EP 20185463 A 20140314; ES 14724574 T 20140314; FR 21C1059 C 20211214; HK 16108704 A 20160720; IL 24137815 A 20150909; IL 28896121 A 20211213; JP 2016503089 A 20140314; JP 2019104944 A 20190605; JP 2022023265 A 20220217; KR 20157029620 A 20140314; NL 301149 C 20211206; NO 2021051 C 20211203; PL 14724574 T 20140314; PT 14724574 T 20140314; RU 2015143965 A 20140314; RU 2019116003 A 20140314; US 201414775911 A 20140314; US 202117401929 A 20210813